Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Cheirif

Cardiovascular Disease Dallas, TX Medical Doctor

NPI 1598703803 CMS profile 116922

8440 Walnut Hill Ln Ste 610, Dallas, TX 75231

Open in the dashboard

General payments

$92,337

461 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$27,625 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Jorge Cheirif of Dallas, TX is reported in the CMS Open Payments database as having received $92,337 across 461 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $27,625 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,506 65
2024 General $1,840 75
2023 General $9,157 59
2022 General $12,687 61
2021 General $11,491 47
2020 General $15,986 55
2019 General $39,669 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Cheirif
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jorge Cheirif were reported at $1,506. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jorge Cheirif Cardiovascular Disease median Middle half National median
2019 $39,669 $450 $127–$1,392 $163
2020 $15,986 $242 $77–$751 $114
2021 $11,491 $335 $101–$1,037 $132
2022 $12,687 $395 $121–$1,211 $149
2023 $9,157 $443 $136–$1,283 $160
2024 $1,840 $450 $136–$1,323 $164
2025 $1,506 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $46,074 94 payments
  2. Sanofi-Aventis U.S. LLC $16,055 18 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13,090 42 payments
  4. AstraZeneca Pharmaceuticals LP $9,757 24 payments
  5. Regeneron Healthcare Solutions, Inc. $1,054 7 payments
  6. Actelion Pharmaceuticals US, Inc. $737 27 payments
  7. Merck Sharp & Dohme Corporation $644 33 payments
  8. Novartis Pharmaceuticals Corporation $588 42 payments
  9. Pfizer Inc. $404 22 payments
  10. Boston Scientific Corporation $387 12 payments
  11. Other $3,547 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $80,651 59 payments
  2. Food and Beverage $8,868 383 payments
  3. Travel and Lodging $2,213 10 payments
  4. Consulting Fee $316 2 payments
  5. Education $233 6 payments
  6. Debt forgiveness $56 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $46,074 94 payments
  2. PRALUENT Cardiovascular $16,025 16 payments
  3. LifeVest $13,090 42 payments
  4. FARXIGA $9,674 19 payments
  5. PRALUENT Cardiovascular And Metabolism $1,054 7 payments
  6. VERQUVO $744 38 payments
  7. UPTRAVI $660 23 payments
  8. LEQVIO $454 34 payments
  9. FFRct $364 4 payments
  10. OPSUMIT $332 11 payments
  11. Other $4,497 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

8,396

Median for Cardiology: 2,533

Drug cost

$1,686,123

Median for Cardiology: $485,213

Branded share of claims

25.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 412 $488,276
Eliquis Apixaban Brand 244 $291,285
Uptravi Selexipag Brand 11 $274,223
Entresto Sacubitril/Valsartan Brand 220 $258,810
Farxiga Dapagliflozin Propanediol Brand 77 $84,553
Jardiance Empagliflozin Brand 61 $59,860
Repatha Sureclick Evolocumab Brand 59 $39,960
Verquvo Vericiguat Brand 35 $34,434
Nexlizet Bempedoic Acid/Ezetimibe Brand 18 $20,970
Praluent Pen Alirocumab Brand 16 $18,348

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$225,794

Of which drugs: $759

Medicare patients

1,330

Average age 77

Services billed

3,801

676 women, 654 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 44%
Atrial fibrillation 37%
Diabetes 33%
Chronic kidney disease 33%
Heart failure 32%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, perflutren lipid microspheres, per ml Q9957 Office 15 23 $759

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $168
$168 11 —
VERQUVO
  • Merck Sharp & Dohme Corporation $149
$149 35 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $93
$93 220 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $85
$85 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record